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Abstract
Background: There is limited information about the challenges of cancer management and attempts at improving
outcomes in Africa. Even though South and North Africa are better resourceds to tackle the burden of breast
cancer, similar poor prognostic factors are common to all countries. The five-year overall Survival rate for breast
cancer patients does not exceed 60% for any low and middle-income country (LMIC) in Africa. In spite of the gains
achieved over the past decade, certain characteristics remain the same such as limited availability of breast
conservation therapies, inadequate access to drugs, few oncology specialists and adherence to harmful socio-
cultural practices. This review on managing breast cancer in Africa is authored by African oncologists who practice
or collaborate in Africa and with hands-on experience with the realities.
Methods: A search was performed via electronic databases from 1999 to 2016. (PubMed/Medline, African Journals
Online) for all literature in English or translated into English, covering the terms “breast cancer in Africa and
developing countries”. One hundred ninety were deemed appropriate.
Results: Breast tumors are diagnosed at earlier ages and later stages than in highincome countries. There is a
higher prevalence of triple-negative cancers. The limitations of poor nursing care and surgery, inadequate access to
radiotherapy, poor availability of basic and modern systemic therapies translate into lower survival rate. Positive
strides in breast cancer management in Africa include increased adaptation of treatment guidelines, improved
pathology services including immuno-histochemistry, expansion and upgrading of radiotherapy equipment across
the continent in addition to more research opportunities.
Conclusion: This review is an update of the management of breast cancer in Africa, taking a look at the
epidemiology, pathology, management resources, outcomes, research and limitations in Africa from the perspective
of oncologists with local experience.
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Background
Publications on breast cancer in Africa start by describ-
ing a large number of patients presenting with advanced
disease, limited access to cancer education, screening,
and care. We have learned from previous studies that
registries are still missing in Africa or are only hospital
based in most regions of the continent. The estimates of
breast cancer incidence are presented as figures but not
with the real data as the current situation, remains still
to be determined [1].
Survival is seldom described and if so only selectively
in a limited number of countries or centers. Cancer
mortality rates in African countries are not comparable
to those of high-income countries (HIC) [1], reaching
unacceptable high proportions.
The Concorde −2 study of 5-year breast cancer survival
from 1995 to 2009 based on the analysis of individual data
from 279 population-based registries in 67 countries,
reported that, in HIC, age-standardized net survival rates
were more than 85%. One country in Africa, Mauritius, a
HIC island nation off the coast of Madagascar, had similar
survival rates of 87.4% (95% CI:78.1–96.7). North African
countries had lower outcomes compared to HIC, for
example, 59.8% (95% CI:48.6–71.1) in Algeria, 76.6% (95%
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CI:55.5–97.7) in Libya (Benghazi registry) and 68.4% (95%
CI:64.5–72.2) in Tunisia. By contrast, data available from
three Sub-Saharan countries, South Africa 53.4% (95%
CI:35.5–71.3), The Gambia 11.9%(95% CI:0–24.7) and
Mali 13.6%(95% CI:0, 0–30.1), were significantly inferior
to other countries around the world [1]. More than 50%
of African women diagnosed with breast cancer die of the
disease [2]. The disease is the most frequent cause of
cancer death in less developed regions, causing one in five
deaths in African women [3], described as a new “shift”
from the previous decade [4]. Breast tumors are diagnosed
a decade or two lower on age at diagnosis and present at
advanced stages compared to developed countries [5, 6].
A higher prevalence of hormone receptor negative and
triple-negative cancers(TNBC) is found in Africa [7]. The
paucity of oncology specialist including nurses and
surgeons, access to radiotherapy, availability of basic and
modern systemic and hormonal therapies and steadfast
adherence to negative socio-cultural beliefs is reflected
in the observed lower survival rates compared to high-
income countries. In spite of the various setbacks, im-
provements in breast cancer management include the
development or adaptation of treatment guidelines,
improved pathology services including immunohisto-
chemistry testing for hormone receptor testing. The
expansion and upgrading of radiotherapy resources,
new collaborations fostered between international orga-
nizations and African cancer treatment facilities will
promote research opportunities and improve outcomes.
Previous reviews were specific to surgery, stage at pres-
entation, pathology services or discussed sub-regions
whereas this paper provides an update on the current state
of breast cancer management in Africa as whole, looking
at epidemiology, clinical presentation, and access to radio-
therapy, systemic therapies, pathology services, outcomes
and new research.
Methods
A search was performed via electronic databases
(Pubmed, Medline, African Journal online) for literature
in English or translated into English covering all aspects
of breast cancer in Africa from 1999 to 2016. One thou-
sand three hundred and twenty articles on the subject
were retrieved under the terms “breast cancer and Africa
or developing countries.” Publications with high em-
phasis on prevention and screening were excluded. Two
hundred and twenty-five articles were relevant to the
subject under review and One hundred and ninety
articles including 15 review articles, were selected.
Results
The majority of publications were from North and West
Africa (60%), others were from East (10%), Central and
South Africa (12%). Other publications (31%) broadly
discussed breast cancer in larger geographical regions i.e.,
Sub-Saharan Africa, developing countries in which discus-
sions specific to Africa were highlighted. Publications
from authors in developed countries and collaborating
international organizations were found in high impact
journals whereas publications from local health personnel
were found in lower impact journals. There were very few
prospective studies and many retrospective studies.
New research findings, epidemiology, practice update,
challenges involved in disease control, differences in
disease characteristics, management practices, and out-
comes are highlighted.
Epidemiology
Non-communicable diseases, including breast cancer,
are on the rise in Africa, presumably due to advances in
health care, translating into longer life expectancy and
increased detection of cancer. Breast cancer incidence
increases with age, and people in Africa are living longer
due to better control of human immunodeficiency virus
(HIV) and other infectious diseases [8]. This section will
discuss prevalence, incidence, and risk factors of breast
cancer in Africa. Eleven studies were found on the epi-
demiology of breast cancer in Africa, including studies
from Zimbabwe, Tunisia, Egypt, Morocco, South Africa,
and Nigeria.
Prevalence
Breast cancer is leading cancer among the female popu-
lation worldwide, as well as in the majority of countries
in Africa, according to data from 26 African countries
for 2012 [9]. In Africa, breast cancer is responsible for
one in four diagnosed cancers and one in five cancer
deaths in women [10].
Incidence
Marked variation exists in the reported incidence of
breast cancer worldwide – from 95 to 100 cases per
100,000 persons in North America, Northern Europe,
and Australia to 13.5–30 per 100,000 women in sub-
Saharan Africa(SSA) [3]. The breast cancer incidence in
Africa continues to increase and is projected to double
by 2050 [11]. In Zimbabwe, a 4.5% annual increase in
breast cancer incidence over the period 1991–2010 has
been noted [11]. Within SSA, there is considerable
regional variation in the estimated incidence of breast
cancer, with 38.9 (per 100,000 women) in Southern
Africa, 38.6 in western Africa, 30.4 in eastern Africa, and
26.8 in central Africa [3]. The high rates in southern
Africa and urban parts of Africa may be due to better
reporting and a higher population of Anglo-Europeans
in those areas [12]. Of note, studies from Tunisia, Egypt,
and Morocco report that North Africa has a greater pro-
portion of inflammatory breast cancer (IBC) among all
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breast cancers than elsewhere in the world; however, the
incidence of IBC in North Africa is in decline [13–15]. As
only a few African countries maintain cancer registries,
accurate prevalence figures are unavailable, although the
global burden of cancer study (GLOBOCAN) data estimate
that in 2012, 94,000 women developed breast cancer [3].
Risk factors
Several studies have investigated breast cancer risk and
various reproductive and anthropometric factors. Use of
oral or injectable contraceptives within the previous 10
years significantly increased risk of breast cancer in
South Africa, with an odds ratio (OR) of 1.66 and 95%
confidence interval (CI) of 1.28–2.16 [16]. Another study
in Nigeria found an inverse relationship between age at
menarche and breast cancer risk (OR: 0.72; 95% CI:
0.54–0.95) [17]. In a Nigerian study of 1233 breast
cancer cases, body mass index (BMI) had an inverse
relationship to risk (OR: 1.22; 95% CI: 1.14–1.32) [18].
Also in Nigeria, height, waist circumference (OR: 2.39;
95% CI: 1.59–3.60), and waist-to-hip ratio (OR: 2.15;
95% CI: 1.61–2.85) showed positive correlation to breast
cancer [18, 19]. A study for North Africa defines a risk
profile in Egyptian and Tunisian women that are more
protective about high-income countries. These are a
higher mean number of children, younger mean age at
first pregnancy, longer mean duration of breastfeeding,
lower mean age at menopause, lower prevalence of
contraceptive use and lower alcohol consumption [13].
In summary, breast cancer is the most prevalent
cancer in African women, although incidence is lower
than in high-income countries. Even though the risk
factors of breast cancer in Africa are similar to those in
high-income countries, the variation in risk factor inci-
dences may account for the differences between African
countries and high-income countries.
Clinical presentation
The clinical presentation of breast cancer in African
women is significantly different compared to their coun-
terparts in high-income countries, as well as from Africa.
Age at presentation
Breast cancer patients in Africa present at a relatively
younger age compared to patients in high-income coun-
tries [7, 20, 21]. The overall mean age of presentation in
West African women is between 35 and 45 years, 10 to
15 years earlier than in women from high-income coun-
tries [22]. Similarly, a 3-year retrospective review of 374
breast cancer patients in Kenya showed a median age of
44 years [6], while the mean age in a Tanzanian cancer
registry was 44.7 years [23].
Stage at presentation
The majority of patients in Africa present with advanced
stage breast cancer, with 89.6% and 72.8% of breast
patients in Kenya and Nigeria respectively presenting
with advanced stage disease [6, 24]. These rates are rela-
tively higher than rates of advanced stage breast cancer
in high-income countries [25]. Studies in South Africa
reported an advanced stage breast cancer incidence of
50 and 55% [25, 26]. However, a Moroccan study re-
ported an incidence of 33% for Stage III and IV breast
cancers [27]. Of note, south and northern African
patients present at earlier stages compared to the rest of
Africa. Table 1. summarizes the data for clinical presen-
tation in the studies reviewed [6, 7, 23–28].
Receptor status
Breast cancers diagnosed among African women report-
edly include a disproportionate number of poor progno-
sis tumors, including hormone receptor negative, and
triple negative. Tumors tend to be larger, with most
being >2 cm. Many of the tumors are hormone receptor
negative, with reported rates of both estrogen receptor
(ER) and progesterone receptor (PR) negativity ranging
from 36 to 79% and 30–87% [Table 1]. Few studies
report on human epidermal growth factor receptor 2
(HER 2) status as its impact is over shadowed by the
high rate of triple negative cancers (TNBC). Over
expression of HER 2 is reported in 18% of Malian
patients, 26% in South Africa, 22% in Uganda, 17.5% in
Sudan, and 27% in Egypt showing differences within the
continent [29–33]. Luyeye et al. compared to breast
cancer molecular subtypes between Congo and
Belgium and found higher Her2 over expression rates
in older Congolese women compared to Belgians [34].
Many African women are diagnosed with triple nega-
tive tumors [6, 7, 23–28]. Triple-negative breast cancer
(TNBC) subtypes account for 12–20% of all breast can-
cer; however, women of African descent tend to have a
high incidence of TNBC translating into poorer out-
comes [35]. The proportion of triple-negative breast
cancers among all breast cancers is 23 and 28% in
Tunisia and Egypt respectively [13, 27].
In summary, there is a lower average age of breast
cancer diagnosis and higher stage at presentation in
Africa compared to high-income countries. There is a
higher proportion of triple-negative breast cancers in
Africa compared to other high-income countries.
Surgical management
Surgery is the primary modality in the management of
resectable breast cancer, and when integrated with other
therapies plays a significant role in controlling locally
advanced or metastatic disease. However, in certain parts
of the world including Africa, surgery may be the only
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treatment option due to limited resources for
complimentary adjuvant therapies. The rates of sur-
gical treatment vary across Africa, ranging from
35.2% in Nigeria to 100% in Cameroon; with the ma-
jority of countries reporting surgical rates between
48 and 75% compared to over 90% in European
countries [26]. The differences in surgical rates could
be a result of the high burden of African women
presenting with unresectable breast cancer.
Factors influencing the choice of surgery
The majority of women in developed countries present
with early stage disease amenable to breast conserving
techniques because of established screening and aware-
ness programs. On the other hand, many women in Africa
require radical mastectomy to control their disease [21].
On average, 50–75% of women present with very ad-
vanced disease in Africa [36]. Islami et al. reported 74 and
81% advanced stage at presentation in Cote d’Ivoire and
the Democratic Republic of Congo respectively [37],
Soliman et al. reported 90% of breast cancer patients
present with advanced disease in Niger; invariably mastec-
tomy is the most common surgical procedure performed
[38]. Reports from Eritrea and Tanzania indicate that up
to 99% of patients undergo mastectomy for various rea-
sons including advanced stage and lack of other modalities
of treatment [39, 40]. Mastectomy and breast conservation
rates in Europe are reported as 30 and 70% respectively,
which is in sharp contrast to 85% mastectomy rates in
Africa [41]. North America reports rising breast conserva-
tion rate (68%) as at 2007 [42].
The indication for breast conserving surgery is limited
early resectable disease and dependent on the availability
of radiation therapy to sterilize the remaining breast
tissue. Borderline resectable tumors can be down
staged to allow for breast conservation with neoadju-
vant chemotherapy. The poor access to radiation
facilities in Africa is a major factor contributing to
the limited access to conserving breast surgery in
many countries. Even where radiotherapy facilities are
available in Africa, very few women are considered
candidates for breast conservation despite achieving
good response rates to neoadjuvant chemotherapy for
various reasons [5]. Maalej et al. reported that even
though half of breast cancer patients present with
resectable disease in Tunisia, the breast conservation
rate was only 17.6% and was dependent on the
surgeon’s preferences [43].
Egyptian women with early stage disease may be
considered poor candidates for breast conservation
because of high illiteracy rate and compounding
cultural influences. These factors do not allow for
regular surveillance of patients following breast con-
servation required to detect early recurrence in the
remaining breast tissue [44].
In a recent review of breast cancer surgery in
Africa, Malawi, Ghana, Rwanda and South Africa
reported higher rates of lumpectomy (45, 40, 29 and
12% respectively) compared to single digit figures
found in other countries [26]. This report may indi-
cate improvement in down staging of tumors, access
to care and breast cancer education. Malawi and
Rwanda do not have radiotherapy facilities, meaning
patients will have to travel to neighboring countries
for radiotherapy and would be of interest to know
the follow-up data for these patients.
Table 1 Clinical presentation of breast cancer by study included in this review
Study Country Patients Reported incidence of advanced
stage breast cancer
Median Age at
Diagnosis
Receptor Status in HIV-
uninfected patients
Otheino-Abinya [6] Kenya 250 89.6% 44
Ikpat [28] Nigeria 300 42.7
Adebamowo [24] Nigeria 250 72.8% 43
Anyanwu [7] Nigeria 179 72% 46.9
Cubasch [25] Soweto, South Africa 1092 50% ER: 58%
PR: 47%
HER2: 22%
TNBC: 19%
Langenhoven [26] Cape Town, South Africa 586 55% 56 ER: 64%
PR: 51%
HER2: 36%
TNBC: 16%
Amir [23] Tanzania 937 44.7
Rais [27] Morocco 980 33% 46 TNBC: 16.5%
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Quality of surgery
Several authors [45, 46] have discussed the inadequacy
of surgical capacities to tackle cancer surgery in LMIC.
Resources including skilled personnel are limited to
main cities limiting access to the rural poor even though
some of the required procedures are basic and could be
performed by general surgeons [25]. In a few African
countries like Malawi by surgeries are performed by
non-physicians, who may not understand the principles
underlying the adequacy of axillary dissections, obtaining
clear margins and proper fixation of surgical specimens
for histological assessment [47]. Economic and political
instability on the continent may be a contributing
factor to the limited number of trained surgical on-
cologist by promoting brain drain resulting from not
only poor remuneration but also suboptimal resources
in the working environment [46]. The continent
needs to invest in the training of oncology specialist
to improve outcomes [48].
Factors contributing to poor compliance to surgery
Breast cancer patients in Africa default mastectomy for
many reasons which include the fear of mastectomy.
The low surgical utilization rates found in some coun-
tries could be explained by the lack of awareness in
detecting early stage disease, long surgical waiting list
leading to the productive use of alternative therapies, a
complexity of navigating health care systems, financial
constraints and illiteracy [31, 49–52].
Breast cancer surgery is considered demeaning and
culturally and spiritually unacceptable [53]. The rate of
mastectomy refusal varies within the continent, an
example being fewer refusal rates in Eritrea and
Cameroon compared to Nigeria [26].
In summary, the quality of breast cancer surgery in Af-
rica is improving but requires an injection of resources
starting with a training of surgeons with oncology skills,
improving access to care and patient education on the
impact of sociocultural myths.
Systemic therapies
The number of publications documenting and detailing
experiences with systemic therapies for breast cancer
management in Africa continues to rise in recent years
but still considered scare. For this reason, comprehen-
sive comparisons of systemic therapy logistics and out-
comes within Africa and the rest of the world was
difficult in the absence of rich data.
Chemotherapy
Cost and access to drugs
The cost of newer and more effective systemic therapies
for cancer continues to rise. For most of Africa, meager
health expenditure budgets, competing for interest and
dwindling donor financial support are hindrances to
accessing life-saving cancer medication with many low-
middle income countries(LMIC) barely satisfying the
WHO essential drug list for cancer [54]. Publications
from Africa repeatedly demonstrate the limited availabil-
ity of some core and newer cancer drugs and the un-
bearable out of pocket payments leading to treatment
non –compliance [5, 36, 40]. Breast cancer activist has
had little success improving access to drugs by lobbying
to reduce a cost of drugs through tax exemptions and
ensuring breast cancer screening, diagnosis and treat-
ment are included in national health insurance schemes.
Breast cancer in Africa is characterized by disease in
younger women with aggressive disease and poor hor-
mone receptor staining which require the use of second
and third generation drugs including Taxane-based
chemotherapy [55–58]. These new drugs are consider-
ably expensive with limited access in very few Sub-
Saharan African health institutions [59–61]. Patients
who are refractory to initial chemotherapy have limited
options for subsequent therapies, which are either un-
available or unaffordable. Southern and northern parts
of Africa have better access to newer cancer medications
and promote the use of national guidelines in an attempt
to standardize management of breast cancer in their
countries [62].
Choice of drugs
Most low- and middle-income countries in Africa ex-
perience severe limitations with drug access, which un-
fortunately could foster the influx of cheap, suboptimal
or fake drugs. Generic brands of systemic therapies have
improved access to life-saving cancer medications with
the promise of very low pricing and availability [63].
For each patient, the financial limitations, inconveni-
ent scheduling of cycles, i.e., weekly versus three weekly,
and a high cost of supportive therapies needed to reduce
toxicity and patient and family beliefs and interferences
influences the choice and sequence of treatments [64]. A
pilot survey of breast cancer management in sub-
Saharan Africa reports that the use of neoadjuvant
chemotherapy was more prevalent and could be a result
of the high burden of locally reported and or large the-
ater waiting time. In this study cyclophosphamide, adria-
mycin and five Fluorouracil combination were the
commonest protocol prescribed in the neoadjuvant and
adjuvant setting [65]. Achieving complete pathological
response rates is associated with improved survival in
patients who received neoadjuvant chemotherapy.
McFarland, et al. in a recent publication, describes
improvements in breast cancer pathological response
rates over a five-year period following neoadjuvant
chemotherapy; from 14 to 43%, with an overall complete
response rate of 26.5% [66]. The introduction of newer
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drugs into neoadjuvant protocols especially Her 2
targeted drugs, Taxanes, and carboplatin for Her2 posi-
tive and TNBC subtypes are associated with the recent
improvements in pathological response rates. Sule at al.,
in 2016 published data on 20 patients in Nigeria who
received at least five cycles of Taxane- based neoadju-
vant chemotherapy, and reported a 67% complete patho-
logical response rate [67]. Other small studies from
Africa report complete pathological response rates of
10–35%, none of the studies included Taxanes, carbopla-
tin or Her 2 targets [68–70]. These rates compare favor-
ably with full pathological rates from developed
countries before the introduction of Taxanes, carboplatin
and targeted therapies [71].
A phase 2 trial conducted in Nigerian patients re-
ported no complete pathological response rate with
single neoadjuvant agent capecitabine, but documented
a 44% overall response rate [72].
Breast cancer patients in Africa are known to abscond
following complete clinical response to neoadjuvant, and
this may influence the high mastectomy rate found in
some parts of Africa [73].
Down staging compliance to chemotherapy
In Cameroon, one-third of breast cancer patients delayed
the first two cycles chemotherapy at least by 2 weeks and
two third cited financial constraints as a compounding
factor [74]. The cost was a major factor contributing to
high noncompliance rates in other countries [39, 75].
Other than the high cost of chemotherapy, side effects of
chemotherapy such as hair loss, nail changes, nausea,
vomiting, and infertility is considered culturally unaccept-
able, driving patients to abscond treatment for traditional
and less invasive unorthodox treatments [44, 76].
Quality of service delivery
The lack of support services to manage toxicities may be
a reason to withhold effective chemotherapy protocols
even where accessible. In some parts of Africa, the choice
and sequencing of chemotherapy protocols is ad hoc. The
prescription and administration of systemic therapies are
by general physicians, surgeons, and non-oncology nurses,
and this negatively impacts optimization of disease control
[45]. Low white cell counts levels in Africans may con-
found the ability to administer full doses of chemotherapy
and the use highly myelo-suppressive protocols especially
in non-experienced hands, notwithstanding the prohibitive
cost of granulocyte stimulating growth factors [77]. The
role of specialized oncology nurses is important for cancer
control through education, counseling, proper administra-
tion of chemotherapy and palliation. Structured oncology
nursing training programs are a necessity for Africa and
other LMIC to improve the quality of cancer care [78].
Targeted therapy
Cost and access to drug
Epidermal Growth Factor Receptors, Vascular Endothe-
lial Growth Factor receptor, Mammalian Target Of
Rapamycin inhibitors, cyclin dependent kinases, pro-
grammed cell death protein one inhibitor either with
single or double blockade of receptors targets are some
of the new drugs developed to target the breast cancer
cell [79]. The discovery of HER 2 targeted therapy has
revolutionized the management of breast cancer. How-
ever, the cost of these life-saving drugs remains, unfortu-
nately, astronomical even for high-income countries
[80]. In 2015, Trastuzumab was included in the World
Health Organisation (WHO) essential drug list for the
management of Her2 positive breast cancer. However,
the cost-effectiveness of this treatment in most LMIC is
under debate [81]. In South and North of Africa where
Trastuzumab, a HER 2 targeted drug is easily available,
there are serious concerns about access [82].
Biosimilars at markedly reduced cost available to
countries like India should be made available to Africa
to save precious lives. The astronomical cost of bio-
marker testing and molecularly targeted drugs brings
into question the cost-effectiveness of promoting exten-
sive molecular profiling of breast cancer in Africa other
than for research purposes.
Hormonal therapy
This class of drugs targets the hormone receptor within
the breast cancer cell. They are indicated only in hor-
mone receptor positive disease, achieving high response
rates, which translate into improved control and survival
in the curative or palliative setting. The accuracy of
receptor testing is dependent on efficient and reliable
pathology services. Countries without these facilities
resort to a blind prescription of hormonal therapies.
Cost and access to drug
Hormonal therapy for breast cancer is one of the most
available treatment options even in poorer countries.
Many companies supply generic Tamoxifen at a very low
cost making it readily available and in some countries
available free of charge [83, 84].
Unlike Tamoxifen, the access and availability of aroma-
tase inhibitors is restricted in most of Africa [22, 85].
Choice of drug
In Africa, patients are more likely to be ER negative,
rendering Tamoxifen ineffective in disease control if pre-
scribed for all breast cancer patients [86, 87]. A recent
meta-analysis of hormone receptor status of breast
cancer patients in Africa indicates that more than half of
African women have hormone positive breast cancer,
disputing the poor receptor status in the majority of
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breast cancer cases [85]. However, this finding from the
study is debatable and is not evident in clinical practice
and will, therefore, require further expanded research.
There are detrimental effects of prescribing Tamoxifen
for negative receptor disease, and it remains apparent
that improving the quality of pathology services is a key
to improving survival [10]. Numerous studies have dem-
onstrated improved outcomes with the use of aromatase
inhibitors in both premenopausal (following ovarian
suppression) and post-menopausal women with receptor
positive breast cancer [88, 89]. The acceptance of ovarian
suppression in premenopausal young African women is
low and a hindrance to prescribing aromatase inhibitors
as primary or second line therapy for hormone receptor
positive disease. Many African countries currently
recognize the importance of receptor testing and are
working towards improving pathology services [90]. As an
example, Madagascar did not have access to hormone
receptor testing until 2011 and are currently reporting a
higher ER negative- rates compared to ER-positive disease,
defining a better application of targeted therapy [91].
Compliance to hormone therapy
Non-adherence to hormone treatment is a common
worldwide problem and ranges 30–72% for adherence
and discontinuation [92].
Small studies from Nigeria and South Africa report 25
and 36% non-adherence rates for Tamoxifen which is
comparable to data from developed countries [93, 94].
In summary, the use of systemic therapies to control
breast cancer in Africa continues to improve as coun-
tries develop and adopt guidelines from developed coun-
tries. Sadly, these improvements are evident mainly in
the middle and higher income countries in the contin-
ent. The impact on outcomes are be dampened by the
lack of access to quality medications, unskilled personnel
and socio-cultural influences in many countries.
Radiotherapy
Access to radiation therapy
The most challenging aspect of providing breast cancer
radiotherapy in Africa is access to radiation therapy
resources. More than 90% of all radiotherapy equipment
is found in South and northern Africa [95]. Twenty-nine
countries in Africa have no access to radiation services,
and even those with these services face prohibitive main-
tenance costs and demands for limited skills. There is
often extreme pressure on these limited resources, lead-
ing to delay in commencement of treatment. With the
majority of patients being diagnosed with a locally
advanced disease, the inclusion of radiation treatments
in the overall management is paramount.
Expanding radiation facilities is a major step to im-
proving outcomes in breast cancer patients with both
primary and metastatic disease. Advanced techniques
such as conformal and planning techniques used in HIC
has been successfully replicated with less sophisticated
but modernized Cobalt-60 teletherapy equipment and
low energy linear accelerators as a pilot in some coun-
tries and has the potential to reduce toxicities associated
with breast irradiation [96, 97]. Through partnerships
with the International Atomic Energy Agency (IAEA)
and other collaborators, many countries are establish-
ing new centers or upgrading existing ones with mod-
ern radiotherapy equipment and training of technical
staff, which will invariably improve access to radio-
therapy services.
Dose prescription
Treatment protocols for curative breast cancer vary
across the continent with some institutions following
international standardized protocols of 5 weeks of daily
radiation; and in others, shortened hypo-fractionated re-
gimes are adopted in increased throughput of patients
on the limited numbers of linear accelerators [98, 99].
Also, hypofractionated regimens are unnecessarily
avoided in some instances where access is only to
cobalt-60 or low energy linear accelerators due to
concerns regarding skin toxicities.
Radiotherapy is a cornerstone of effective palliative
care, essential for managing bone pain and unresectable
locally advanced disease complicated by ulceration and
bleeding. A survey of patterns of palliative radiation has
shown that oncologists in Africa conform to cost-
effective single fractions in bone metastases but are
more likely to use longer fractionation schedules for
local disease [100].
Factors affecting compliance to treatment
Interruption of radiotherapy treatments are a frequent
occurrence as the daily costs of traveling for therapy can
be significant [101]. Many centers in Africa charge user
fees, which for the impoverished lead to a high rate of
non-compliance. Data on outcomes the following radio-
therapy for breast cancer patients in Africa is lacking,
with no particular research being published in the last
decade detailing efficacy data, abandonment or cost of
treatment.
In summary, the limited radiotherapy access in Africa
is a major setback to improving breast cancer outcomes
considering the high burden of advanced disease on the
continent.
Managing HIV positive breast cancer in Africa
Chemotherapy toxicities
Although the cluster of differentiation 4 (CD4) count in
HIV-infected patients is not associated with age and
stage of breast cancer, CD4 count at diagnosis may affect
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chemotherapy tolerance [102]. Langenhoven et al., in a
South African cohort, reported that more than 84% of
breast cancer patients, including 19 who were HIV-
infected, who initiated systemic chemotherapy com-
pleted it without severe toxicity, regardless of their HIV
status [26]. This report was found despite a mean de-
cline in CD4 count during chemotherapy from 477 cells/
μL to 333 cells/μL. There was no statistically significant
difference in hematologic toxicity requiring dose modifi-
cation. However, grade 3 or 4 lymphocytopenia devel-
oped only in the HIV-infected patients (26.4%; p =
0.001). Additionally, there was no data on the HIV-
infected patients receiving antiretroviral therapy (ART)
concurrently with chemotherapy, with scant details of
the ART regimen [26].
These findings suggest that while HIV/AIDS may
cause some chemotoxicity in patients with a low CD4
count, a normal CD4 count does not reduce chemother-
apy tolerance. Low CD4 count, may have reduced treat-
ment efficacy and treatment adequacy due to poor
adherence, dose adjustments, treatment delays and early
discontinuation of therapy [103–105].
There are no studies examining treatment outcomes
with surgery and radiation therapy in patients with HIV/
AIDS and breast cancer in Africa.
In summary, HIV positive breast cancer patients in
Africa should be managed like HIV negative patients
under proper supervision by skilled clinicians, paying
attention to supportive care needs.
Outcomes
Compared with data on the incidence and overall bur-
den of the disease, there is a significant paucity of data
on breast cancer outcomes including overall survival,
quality of life and survivorship issues. Large population–
based outcome reports are lacking due to various factors
such as delay in diagnosis, lack or interruptions of treat-
ment, heterogeneity and difficulty of access to screening,
diagnosis and treatment and lack of high-quality
population-based cancer registries [106]. Currently avail-
able data point to a very high mortality/incidence ratio
of 0.55 in Central Africa as compared to 0.16 in the
United States [107]. Most publications on Breast cancer
treatments and outcomes are from the facility- or
hospital-based case series [61]. Nonetheless, these case
series provide valuable data. For example, adjuvant,
chemotherapy and radiotherapy were given to 44.8 and
11.7% of patients with an overall 5-year survival of
21.8% at the Bugando Medical Center in Tanzania [40].
A retrospective study of 152 patients with triple negative
breast cancer in Morocco reported with a 5-year overall
survival of 76.5%. The outcome was by literature data
from North America and Spain, especially in young age
at high-grade diagnosis tumors, advanced stage at
diagnosis, and a short time to relapse [20, 27]. Despite
high response rate to chemotherapy, the overall progno-
sis of this subset of tumors remains poor. A recent pub-
lication from Accra, Ghana reports a 5-year overall
survival of 91.94% for stage one, 15.09% for stage four
and cumulative 5-year overall survival of 47.9% [108].
Increasingly reports and analysis such as treatment
rates, rates of treatment adherence, local recurrence and
presentation at late stages thought to be of importance in
resource constraint regions are being published [40, 100].
Treatment outcomes generated from prospective clin-
ical trials are scarce. Recent efforts to rectify this situ-
ation include the study of neoadjuvant Capecitabine
chemotherapy in newly diagnosed women with advanced
breast cancer in Nigeria [72]. This phase II study indi-
cated that conducting high-quality prospective trials are
feasible in resource-constrained settings and highlighted
the challenges associated with generating high-quality
patient outcome data such as slow accrual leading to
early closure.
Poorly kept medical records and losses to follow-up of
patients hamper data collection on outcomes. The
African Breast Cancer-Disparities in Outcomes (ABC-
DO) study is a prospective hospital-based study of over-
all survival, quality of life (QoL), delays in diagnosis and
treatment in five African countries [109]. This study,
which is underway utilizes mobile devices to capture the
data of 2000 women over 3 years and will overcome
traditional barriers to collecting patient-outcome data by
harnessing the recent explosion of telecommunication in
the continent.
In summary, reported outcomes for breast cancer
interventions are scarce but show a positive trend. The
poor patient follow-up culture is a major contributing
factor to reporting. With improvements in local and
collaborative research skills development in Africa, there
should be improvements in outcomes data over the next
decade.
Future research
Although there have been significant local and global
collaborative efforts to address research needs of breast
cancer in Africa, critical research gaps remain in basic,
translational, clinical and health services research. Inte-
gration of genomic medicine research findings in breast
cancer prevention, screening, diagnosis, and treatment is
significantly lagging behind in Africa [110]. In addition
to research into the different and complex tumor biology
of breast cancer in Africa [111], other research priorities
including response to treatment, developing validated
markers for chemosensitivity and radiosensitivity to
guide treatment, understanding the optimal duration,
sequencing and logical combinations of treatment for
improved personal therapy. LMICs are societies in
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transition, therefore research in lifestyle changes such as
diet and weight [112], hormonal influences and inter-
action with other non- communicable diseases(NCD)
can shed light on the epidemiology of breast cancer in
Africa and elucidate any changing trends in the biology
of the disease. Other priorities include psychosocial and
cultural dimensions, outcomes and survivorship. Trad-
itionally personalized therapy is thought to be of more
importance in high-income settings. However, given the
cost of access to diagnosis and treatment in resource-
limited settings, it is prudent to invest in research
informing individualized, outcome-based approach to
diagnosis and treatment to maximize rational use of
limited resources.
Infrastructural investment enablers for research in
breast cancer in Africa will require strategic planning to
integrate research in cancer control plans of the contin-
ent as a whole in partnership with stakeholders includ-
ing the international community. Also needed is the
investment in capacity building, training of researchers
and health professionals in addition to the creation of
innovative programs to encourage collaborative cross-
disciplinary working practices [113].
Summary
The situation in Africa continues to show a slow pro-
gression of improved outcomes for breast cancer pa-
tients compared with the rest of the developing world.
Possible reasons may include the inadequacy of health
care infrastructure in many countries, poverty, limited
expenditure of health budget on cancer, increasing
breast cancer burden with late diagnosis, lack of contin-
ued education and awareness programs. Pathology in
Africa needs to improve faster than at the present speed
and the number of those who have the skills and know-
ledge to decipher the diagnosis becomes an urgent issue
to address.
However, the outlook on some fronts calls for opti-
mism. Many African countries are now working together
to create national and international alliances to improve
cancer care and therefore breast cancer care should also
benefit from a more systematic approach. Increased
awareness and education associated with efficient
models to facilitate down staging of the disease remain
essential in Africa.
Conclusion
As more and more governments and organizations make
finalizing cancer control plans a priority, guidelines and
policies for breast cancer care on the continent will con-
tinue to improve. The outlook for optimism will keep on
increasing as well as the survival and the quality of life
for those affected by the disease. Forming consortiums
should be fostered, whereby better-resourced regions in
Africa could serve as mentors, striving to improve breast
cancer survival on the continent.
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